This page was translated from Chinese by AI. If anything differs, the Chinese version prevails.
EGFR 표적치료（레이저티닙 등） · EGFR-targeted therapy (incl. lazertinib) · Medication
EGFR-targeted therapy (incl. lazertinib)
EGFR gene mutations are common in lung adenocarcinoma in East Asian patients. Patients with a mutation can take drugs that target EGFR. Lazertinib, developed in Korea (Korean brand name Leclaza), was approved by the US FDA in August 2024 for use with amivantamab as first-line treatment, the first Korean-made cancer drug approved in the United States.
Background: Lazertinib was licensed in and developed by Korea's Yuhan Corporation (유한양행) and sublicensed to Janssen, part of Johnson & Johnson; approved in Korea in 2021 and by the US FDA in August 2024[1][2]
| Advantages | Limitations |
|---|---|
| Mostly oral medication; MARIPOSA trial: median progression-free survival 23.7 months for the combination versus 16.6 months for osimertinib alone | Only works in patients with specific EGFR mutations; genetic testing is needed first; Most patients develop resistance after long-term use |
Used for
Offered at
Asan Medical Center, Seoul, Korea University Anam Hospital, Severance Hospital, Yonsei University, Samsung Medical Center, Seoul National University Hospital